Semaglutide vs Tirzepatide: Research Comparison
A Side-By-Side Research Comparison Of Semaglutide And Tirzepatide - single GLP-1 versus dual GLP-1/GIP incretin agonists in metabolic research. This Reference Compares Mechanism, Evidence Tier, Molecular Identity, And Pharmacokinetics For Qualified Researchers. For In Vitro Laboratory Research Use Only. Not Medical Advice Or Dosing Guidance.
Side-By-Side Comparison
| Semaglutide | Tirzepatide | |
|---|---|---|
| Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
| Compound Class | GLP-1 receptor agonist; fatty-acid conjugated 31-amino-acid peptide analog of human GLP-1 | Dual GIP/GLP-1 receptor co-agonist (twincretin); synthetic 39-residue peptide with C18 fatty diacid for albumin binding |
| Evidence Tier | Approved Drug | Approved Drug |
| Molecular Target | GLP-1 receptor (GLP1R); cAMP/PKA signaling; pancreatic beta-cell insulin secretion; hypothalamic appetite suppression; gastric emptying delay | GIPR (GIP receptor) + GLP-1R (GLP-1 receptor); dual incretin axis activation; pancreatic insulin secretion and hypothalamic appetite suppression |
| Molecular Weight | 4113.58 Da | 4813.45 Da |
| Amino Acid Sequence | 31-aa GLP-1 analog (Aib2, C18 diacid) | 39-aa acylated peptide (C20 diacid) |
| CAS Number | 910463-68-2 | 2023788-19-2 |
| Half-Life | ~1 week | ~1 week |
| Studied For | Type 2 diabetes management, Chronic weight management / obesity, Cardiovascular risk reduction, HbA1c lowering | Type 2 diabetes management, Chronic weight management / obesity, Obstructive sleep apnea in obesity (FDA approved 2024), Non-alcoholic fatty liver disease (NAFLD/MASH) |
About Semaglutide
The approved GLP-1 weight-loss and diabetes drug; compounded versions carry FDA cautions.
Read The Full Semaglutide MonographAbout Tirzepatide
The approved dual-incretin weight-loss and diabetes drug; compounded versions are not FDA-evaluated.
Read The Full Tirzepatide MonographKey Differences
- Primary molecular target differs: Semaglutide acts on GLP-1 receptor (GLP1R); cAMP/PKA signaling; pancreatic beta-cell insulin secretion; hypothalamic appetite suppression; gastric emptying delay; Tirzepatide acts on GIPR (GIP receptor) + GLP-1R (GLP-1 receptor); dual incretin axis activation; pancreatic insulin secretion and hypothalamic appetite suppression.
Continue Researching
This Comparison Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption, Diagnosis, Or Treatment. See The Full Research Disclaimer.